Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women

Ali Cenk Ozay, Ozlen Emekci Ozay, Recep Emre Okyay, Erkan Cagliyan, Tuncay Kume, Bulent Gulekli, Ali Cenk Ozay, Ozlen Emekci Ozay, Recep Emre Okyay, Erkan Cagliyan, Tuncay Kume, Bulent Gulekli

Abstract

Recently, myoinositol (myo-ins) and folic acid combination has gained an important role for treating Polycystic Ovary Syndrome (PCOS), in addition to combined oral contraceptives (COC). We aimed to examine myo-ins effects on anti-Mullerian hormone (AMH) levels and compare them with those ones obtained administering COC. In this prospective study, 137 PCOS patients, diagnosed according to Rotterdam criteria and admitted to the Reproductive Endocrinology and Infertility Outpatient Clinic at Dokuz Eylul University (Izmir, Turkey), were included. After randomization to COC (n = 60) and myo-ins (n = 77) arms, anthropometric measurements, blood pressure, Modified Ferriman Gallwey scores were calculated. Biochemical and hormonal analysis were performed, and LH/FSH and Apo B/A1 ratios were calculated. Data analysis was carried out in demographically and clinically matched 106 patients (COC = 54; myo-ins = 52). After 3-month treatment, increase in HDL and decreases in LH and LH/FSH ratio were statistically more significant only in COC group when compared with baseline (in both cases p > 0.05). In myo-ins group, fasting glucose, LDL, DHEAS, total cholesterol, and prolactin levels decreased significantly (for all p < 0.05). Progesterone and AMH levels, ovarian volume, ovarian antral follicle, and total antral follicle counts lessened significantly in both groups (for all p < 0.05). In PCOS treatment, MYO is observed more effective in reductions of total ovarian volume and AMH levels.

Conflict of interest statement

There is no conflict of interests that could be perceived as prejudicing the impartiality of the research reported.

Figures

Figure 1
Figure 1
Flow chart of the study.

References

    1. La Marca A., Sighinolfi G., Radi D., et al. Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART) Human Reproduction Update. 2010;16(2):113–130. doi: 10.1093/humupd/dmp036.
    1. Piltonen T., Morin-Papunen L., Koivunen R., Perheentupa A., Ruokonen A., Tapanainen J. S. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Human Reproduction. 2005;20(7):1820–1826. doi: 10.1093/humrep/deh850.
    1. Jonard S., Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Human Reproduction Update. 2004;10(2):107–117. doi: 10.1093/humupd/dmh010.
    1. Tsilchorozidou T., Overton C., Conway G. S. The pathophysiology of polycystic ovary syndrome. Clinical Endocrinology. 2004;60(1):1–17. doi: 10.1046/j.1365-2265.2003.01842.x.
    1. Alexander C. J., Tangchitnob E. P., Lepor N. E. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Reviews in Cardiovascular Medicine. 2009;10(2):83–90.
    1. Apridonidze T., Essah P. A., Iuorno M. J., Nestler J. E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 2005;90(4):1929–1935. doi: 10.1210/jc.2004-1045.
    1. Baillargeon J.-P., Nestler J. E. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? Journal of Clinical Endocrinology and Metabolism. 2006;91(1):22–24. doi: 10.1210/jc.2005-1804.
    1. Cheang K. I., Sharma S. T., Nestler J. E. Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? Gynecological Endocrinology. 2006;22(11):595–604. doi: 10.1080/09513590601005847.
    1. Kane M. T. The effects of water-soluble vitamins on the expansion of rabbit blastocysts in vitro. Journal of Experimental Zoology. 1988;245(2):220–223. doi: 10.1002/jez.1402450211.
    1. Beemster P., Groenen P., Steegers-Theunissen R. Involvement of inositol in reproduction. Nutrition Reviews. 2002;60(3):80–87. doi: 10.1301/00296640260042748.
    1. Morgante G., Orvieto R., Di Sabatino A., Musacchio M. C., De Leo V. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertility and Sterility. 2011;95(8):2642–2644. doi: 10.1016/j.fertnstert.2011.01.035.
    1. Galazis N., Galazi M., Atiomo W. D-chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecological Endocrinology. 2011;27(4):256–262. doi: 10.3109/09513590.2010.538099.
    1. Unfer V., Porcaro G. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Review of Clinical Pharmacology. 2014;7(5):623–631. doi: 10.1586/17512433.2014.925795.
    1. Cook C. L., Siow Y., Brenner A. G., Fallat M. E. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertility and Sterility. 2002;77(1):141–146. doi: 10.1016/s0015-0282(01)02944-2.
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility. 2004;81(1):19–25. doi: 10.1016/j.fertnstert.2003.10.004.
    1. Papaleo E., Unfer V., Baillargeon J.-P., et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecological Endocrinology. 2007;23(12):700–703. doi: 10.1080/09513590701672405.
    1. Gerli S., Papaleo E., Ferrari A., Di Renzo G. C. Randomized, double blind placebo-controlled trial: effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences. 2007;11(5):347–354.
    1. İliodromiti S., Kelsey T. W., Anderson R. A., Nelson S. M. Can anti-Müllerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. Journal of Clinical Endocrinology and Metabolism. 2013;98(8):3332–3340. doi: 10.1210/jc.2013-1393.
    1. La Marca A., Orvieto R., Giulini S., Jasonni V. M., Volpe A., De Leo V. Müllerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertility and Sterility. 2004;82(4):970–972. doi: 10.1016/j.fertnstert.2004.06.001.
    1. Chen M.-J., Yang W.-S., Chen C.-L., Wu M.-Y., Yang Y.-S., Ho H.-N. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Human Reproduction. 2008;23(4):952–957. doi: 10.1093/humrep/den015.
    1. Eilertsen T. B., Vanky E., Carlsen S. M. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced. Human Reproduction. 2012;27(8):2494–2502. doi: 10.1093/humrep/des213.
    1. Pigny P., Merlen E., Robert Y., et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. The Journal of Clinical Endocrinology & Metabolism. 2000;88(12):5957–5962.
    1. Golland I. M., Elstein M. E. Results of an open one-year study with Diane-35 in women with polycystic ovarian syndrome. Annals of the New York Academy of Sciences. 1993;687:263–271. doi: 10.1111/j.1749-6632.1993.tb43875.x.
    1. Elter K., Imir G., Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol–cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction. 2002;17(7):1729–1737. doi: 10.1093/humrep/17.7.1729.
    1. Genazzani A. D., Lanzoni C., Ricchieri F., Jasonni V. M. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecological Endocrinology. 2008;24(3):139–144. doi: 10.1080/09513590801893232.
    1. Genazzani A. D., Santagni S., Ricchieri F., et al. Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research. 2014;40(5):1353–1360. doi: 10.1111/jog.12319.
    1. Li H. W., Wong C. Y., Yeung W. S., Ho P. C., Ng E. H. Serum anti-müllerian hormone level is not altered in women using hormonal contraceptives. Contraception. 2011;83(6):582–585. doi: 10.1016/j.contraception.2010.09.007.
    1. Fábregues F., Castelo-Branco C., Carmona F., Guimerá M., Casamitjana R., Balasch J. The effect of different hormone therapies on anti-müllerian hormone serum levels in anovulatory women of reproductive age. Gynecological Endocrinology. 2011;27(4):216–224. doi: 10.3109/09513590.2010.487595.
    1. Kallio S., Puurunen J., Ruokonen A., Vaskivuo T., Piltonen T., Tapanainen J. S. Antimüllerian hormone levels decrease in women using combined contraception independently of administration route. Fertility and Sterility. 2013;99(5):1305–1310. doi: 10.1016/j.fertnstert.2012.11.034.
    1. La Marca A., Grisendi V., Dondi G., Sighinolfi G., Cianci A. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecological Endocrinology. 2015;31(1):52–56. doi: 10.3109/09513590.2014.964201.
    1. Zacchè M. M., Caputo L., Filippis S., Zacchè G., Dindelli M., Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecological Endocrinology. 2009;25(8):508–513. doi: 10.1080/09513590903015544.
    1. Villaseca P., Hormaza P., Cärdenas I., Oestreicher E., Arteaga E. Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes. European Journal of Contraception and Reproductive Health Care. 2004;9(3):155–165. doi: 10.1080/13625180400007751.
    1. Minozzi M., Costantino D., Guaraldi C., Unfer V. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecological Endocrinology. 2011;27(11):920–924. doi: 10.3109/09513590.2011.564685.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel